An Open Label, Balanced, Randomized, Two Treatment, Two Sequence, Two Period, Cross-Over, Single-Dose, Comparative Oral Bioavailability Study Of Letrozole 2.5 mg Tablets (Test) of Dr.Reddy's Laboratories Ltd And Femara 2.5 mg Tablets (Reference) of Novartis Pharmaceuticals Corporation, USA In Healthy, Post Menopausal Women Subjects Under Fasting Conditions.
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Letrozole (Primary)
- Indications Breast cancer; Endometrial cancer
- Focus Pharmacokinetics
Most Recent Events
- 27 Jun 2011 Biomarkers information updated
- 20 Jun 2011 New trial record